Combined sodium and calcium channel blockade in prevention of lethal arrhythmias

Journal of Cardiovascular Pharmacology

Volumn 41, Issue 5, 2003, Pages 665-670

  Adamson, Philip B ^a   Vanoli, Emilio ^a,b   Shibano, Toshiro ^c   Foreman, Robert D ^a   Schwartz, Peter J ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

Autonomic; Calcium channel; Death; Levosemotiadil; Myocardial infarction; Nervous system; Sodium channel; Sudden; Ventricular fibrillation

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; ISOPRENALINE; LEVOSEMOTIADIL; PROPRANOLOL; SODIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CHANNEL GATING; CHRONOTROPISM; CONTROLLED STUDY; DOG; DRUG MEGADOSE; DRUG POTENCY; HEART ARRHYTHMIA; HEART INFARCTION; HEART RATE; HEART VENTRICLE FIBRILLATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SUDDEN DEATH; TREADMILL EXERCISE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; DEATH, SUDDEN, CARDIAC; DEPRESSION, CHEMICAL; DOGS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEART RATE; ISOPROTERENOL; MYOCARDIAL INFARCTION; PHYSICAL CONDITIONING, ANIMAL; PROPRANOLOL; SODIUM CHANNEL BLOCKERS; THIAZOLES; VENTRICULAR FIBRILLATION;

EID: 0037407167     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200305000-00001     Document Type: Article

References (42)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-12.
2. Waldo AL, Camm AJ, deRuyter H, et al., for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet. 1996;348:7-12.
3. Julian DG, Camm AJ, Frangin G, et al., on behalfofthe EMIAT investigators. The European Myocardial Infarct Amiodarone Trial (EMIAT): the effect of amiodarone on mortality in patients with left ventricular dysfunction surviving a recent myocardial infarction. Lancet. 1997;349:667-74.
4. Cairns JA, Connolly SJ, Roberts R, et al., for the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet. 1997;349:675-82.
5. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-65.
6. Azimilide Post-Infarct Survival Evaluation (ALIVE) Investigators. Late Breaking Clinical Trials session at the American Heart Association Scientific Sessions, Anaheim, California, USA, November 2001.
7. IMPACT Research Group. International mexiletine and placebo antiarrhythmic coronary trial I. Report on arrhythmia and other findings. J Am Coll Cardiol. 1984;4:1148-63.
8. Vanoli E, Priori SG, Nakagawa H, et al. Sympathetic activation, ventricular repolarization and IKr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol. 1995;25:1609-14.
9. Bigger JT Jr, Breithardt G, Brown AM, for the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J. 1991;12:1112-31, and Circulation. 1991;84:1831-51.
10. Bigger JT Jr, Breithardt G, Brown AM, for the Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Eur Heart J. 1991;12:1112-31, and Circulation. 1991;84:1831-51.
11. Carmeliet E. Cardiac ionic currents and acute ischemia. Physiol Rev. 1999;79:917-1017.
12. Elharrar V, Gaum WE, Zipes DP. Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs. Am J Cardiol. 1977;39:544-9.
13. Patterson E. In: Sperelakis N, ed. Physiology and pathophysiology of the heart, 3rd ed. Kluwer Academic Publishers, 1995:547-63.
14. Shaw RM, Rudy Y. Ionic mechanisms of propagation in cardiac tissue: roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res. 1997;81:727-41.
15. Leitch JW, McElduff P, Dobson A, et al. Outcome with calcium channel antagonists after myocardial infarction: a community-based study. J Am Coll Cardiol. 1998;31:111-7.
16. Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation. 1998;80:1571-9.
17. Hohnloser SH, Woosley RL. Sotalol. N Engl J Med. 1994;331:31-8.
18. Julian DG, Prescott RJ, Jackson FS, et al. A controlled trial of sotalol for 1 year after myocardial infarction. Lancet. 1982:1142-7.
19. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med. 1993;329:452-8.
20. ++ channel blocker, SD-3212: a comparison with its enantiomer (SD-3211). Drug Dev Res. 1991;22:293-8.
21. ++ channel blocker, in anesthetized dogs with myocardial infarction in comparison with its enantiomer (SD-3211) and bepridil. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:688-95.
22. Kodama I, Suzuki R, Maruyama K, et al. Electrophysiological effects of SD-3212, a new antiarrhythmic agent with vasodilator action, on guineapig ventricular cells. Br J Pharmacol. 1995;114:503-9.
23. Kodama I, Suzuki R, Honjo H, et al. Electropharmacology of SD-3212, a new antiarrhythmic agent. Cardiovasc Drug Rev. 1996;14:135-47.
24. Koidl B, Miyawaki N, Tritthart HA. A novel benzothiazine Ca2+ channel antagonist, semotiadil, inhibits cardiac L-type Ca2+ currents. Eur J Pharmacol. 1997;322:243-7.
25. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction: an experimental preparation for sudden cardiac death. Circulation. 1984;69:780-90.
26. Schwartz PJ, Vanoli E, Stramba-Badiale M, et al. Autonomic mechanisms and sudden death: new insights from the analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78:969-73.
27. Hull SS Jr, Evans AR, Vanoli E, et al. Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. J Am Coll Cardiol. 1990;16:978-85.
28. Vanoli E, De Ferrari GM, Stramba-Badiale M, et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res. 1991;68:429-35.
29. Adamson PB, Huang MH, Vanoli E, et al. Unexpected interaction between beta-adrenergic blockade and heart rate variability before and after myocardial infarction: a longitudinal study in dogs at high and low risk for sudden death. Circulation. 1994;90:976-82.
30. + channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity. J Cardiovasc Pharmacol. 1995;26:847-54.
31. Adamson PB, Vanoli E, Hull SS Jr, et al. Antifibrillatory effect of ersentilide, a new potassium channel and beta-adrenergic blocker in conscious dogs with a healed myocardial infarction. Cardiovasc Res. 1998;40:56-63.
32. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev. 1989;69:1049-149.
33. La Rovere MT, Bigger JT Jr, Marcus FI, et al., for the ATRAMI Investigators. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 1998;351:478-84.
34. Vanoli E, Hull SS, Adamson PB, et al. Prolongation of repolarization by Ikr and Iks blockade in the prevention of ischemic ventricular fibrillation after myocardial infarction. Eur Heart J. 1997:18(Suppl):263. Abstract.
35. De Ferrari GM, Salvati P, Grossoni M, et al. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death: a study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. J Am Coll Cardiol. 1993;22:283-90.
36. Freemantle N, Cleland J, Young P, et al. β Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-7.
37. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
38. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERITHF). Lancet. 1999;353:2001-7.
39. Schwartz PJ, Motolese M, Pollavini G, et al. Prevention of sudden cardiac death after a first myocardial infarction by pharmacologic or surgical antiadrenergic interventions. J Cardiovasc Electrophysiol. 1992;3:2-16.
40. Billman GE, Schwartz PJ, Stone HL. The effects of daily exercise on susceptibility to sudden death. Circulation. 1984;69:1182-9.
41. Hull SS Jr, Vanoli E, Adamson PB, et al. Exercise training confers anticipatory protection from sudden death during acute myocardial ischemia. Circulation. 1994;89:548-52.
42. Schwartz PJ. Do animal models have clinical value? Am J Cardiol. 1998;81:14D-20D.